Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Fat stored around internal organs in the abdominal cavity, associated with increased metabolic and cardiovascular disease risk compared to subcutaneous fat stored under the skin
JAMA Psychiatry 82, 395405
Medical Eligibility Required Semaglutide and Tirzepatide cannot be prescribed to individuals with the following conditions: BMI under 27, eating disorders, Type 1 diabetes, gallbladder disease, substance abuse, recent bariatric surgery (within the past 6 months), pancreatitis or history of recurrent pancreatitis while taking a GLP-1 medication, medullary thyroid cancer, current pregnancy or breastfeeding, plans to become pregnant, diabetic retinopathy, multiple endocrine neoplasia type 2 (MEN2) or family history of MEN2, serious gastrointestinal disorders, or history of allergic reaction to Tirzepatide or Semaglutide
It is not intended for human or animal administration , and must not be used for diagnostic, therapeutic, or clinical applications
Xu et al., 2021
As their use has expanded beyond their initial indications, GLP-1 receptor agonists are poised to have more far-reaching societal impacts, influencing aspects of public health, healthcare economics, as well as even social perceptions of obesity and weight management
US$ 24.06
US$ 25.93
US$ 26.20
US$ 28.80
US$ 29.01
